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Abstract
Introduction: Gene therapy continues to grow as an important area of research, primarily because of its potential in the
treatment of disease. One significant area where there is a need for better understanding is in improving the efficiency of
oligonucleotide delivery to the cell and indeed, following delivery, the characterization of the effects on the cell.
Methods: In this report, we compare different transfection reagents as delivery vehicles for gold nanoparticles
functionalized with DNA oligonucleotides, and quantify their relative transfection efficiencies. The inhibitory properties of
small interfering RNA (siRNA), single-stranded RNA (ssRNA) and single-stranded DNA (ssDNA) sequences targeted to human
metallothionein hMT-IIa are also quantified in HeLa cells. Techniques used in this study include fluorescence and confocal
microscopy, qPCR and Western analysis.
Findings: We show that the use of transfection reagents does significantly increase nanoparticle transfection efficiencies.
Furthermore, siRNA, ssRNA and ssDNA sequences all have comparable inhibitory properties to ssDNA sequences
immobilized onto gold nanoparticles. We also show that functionalized gold nanoparticles can co-localize with
autophagosomes and illustrate other factors that can affect data collection and interpretation when performing studies
with functionalized nanoparticles.
Conclusions: The desired outcome for biological knockdown studies is the efficient reduction of a specific target; which we
demonstrate by using ssDNA inhibitory sequences targeted to human metallothionein IIa gene transcripts that result in the
knockdown of both the mRNA transcript and the target protein.
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Introduction
Gene therapy has become a key focus of biomedical research, as
a potential treatment for numerous genetic diseases, including
cancer [1–2]. However, the translation of this technique into
clinical practice has been limited by the low efficiency of
therapeutic agent delivery [3]. The most common approach to
delivery in vitro involves the use of recombinant viruses as gene
carriers due to their high transduction efficiencies, which can
result in high levels of protein expression [4]. However their use in
vivo has been hampered by the fact that many of the viral proteins
trigger strong immune responses and scaling up recombinant
virus-based delivery systems remains challenging [5–7].
Non-viral gene delivery systems, including cationic lipids,
polymers, dendrimers, and peptides [8–12], show significantly
reduced transfection efficiencies compared to the viral systems.
Recently, a new avenue of research has focused on nanoparticles
as delivery vehicles. Careful engineering of their surface properties
with specific recognition elements such as antibodies has provided
an ability to target specific cells (particularly cancer cells) [13–14].
In fact, vectors based upon a variety of nanoscale carriers,
including carbon nanotubes, iron oxide, silica, and gold nanopar-
ticles have all demonstrated successful gene delivery [15–20]. Gold
nanoparticles are of particular interest as they are biologically
inert, which by implication suggests that they should not be
cytotoxic [21]. They are easily synthesized and, as stated, are
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readily functionalized using established thiol chemistries, enabling
the engineering of the surface with receptors (or indeed more
subtle changes in the physico-chemical properties). A complex
picture has now emerged within the literature, where nanoparticle
biocompatibility can be seen to be dependent upon dose, cell type
and surface properties. For example, while no toxicity has been
found in studies using gold nanoparticles in BHK21 and HepG2
cells, in others cell lines such as A549, the opposite is true
(evidenced by concentration-dependent morphological changes, as
well as decreased cell viability, as the gold nanoparticle
concentration increased [19,22–24]).
The fact that the surface of gold nanoparticles offers well
established routes for functionality makes them appealing vehicles.
Charged or hydrophobic motifs can be readily bound to the
surface, and indeed can be combined with modification protocols
that include targeting moieties such as antibodies and receptors.
These too can be mixed with a payload such as double-stranded
DNA (dsDNA) or single-stranded DNA (ssDNA), which is then
transfected into cells [25–29]. In one example, Rosi et al. [29]
demonstrated the knockdown of genetically-encoded enhanced
green fluorescent protein (EGFP) after transfection with ssDNA-
functionalized gold nanoparticles by measuring fluorescence of the
residual target protein in the cell. In a more recent study, Kim et al.
[3] were able to demonstrate the knockdown of p53 protein in
HeLa cells using ssDNA-functionalized gold nanoparticles.
Nanoparticles have been shown to enter cells in one of two
ways, either by passive uptake, possibly diffusion [30], or by
endocytosis [31]. In the latter case, the particles migrate through
the cells via a variety of different vesicles to reach the nucleus [32–
33]. The different transfection reagents that have been developed
to facilitate their uptake either by a passive or active mode,
influence not only the efficiency of transfection, but also the
localization of the payload after it enters the cell, leading to a
complex array of factors that needs to be fully understood to
inform a rational strategy if these agents are to be used in gene
therapy.
Here we compare the effect of different transfection reagents on
the insertion and localization of ssDNA-functionalized gold
nanoparticles targeted at metallothionein-IIA (MT-IIA), in HeLa
cells. Metallothioneins are a family of ubiquitous low molecular
weight proteins that have well-established regulatory roles in the
cell [34], making them a target of choice for applications in metal
ion homeostasis, in the detoxification of heavy metals and as
protective cellular stress proteins [34–35]. They also play an
integral role in cell survival via their interaction with the
transcription factors NF-kB and p53; and elevated metallothionein
levels have been found in a number of cancers [36–38]. MT-IIA
accounts for approximately 50% of the total cellular metallothio-
nein protein [39], and is induced by a wide variety of
environmental stresses and agents [34–35,40]. Here, we used
cadmium to manipulate the levels of the MT-IIA in the cell, to
calibrate gene silencing effects (Karin et al. [39]).
We now describe a method to quantify the gene silencing
properties of small interfering RNA (siRNA), single-stranded RNA
(ssRNA) and ssDNA, both free and bound to nanoparticles. We
show that ssDNA-dependent knockdown of gene expression using
functionalized gold nanoparticles occurs at the mRNA level and
results in the loss of the specific mRNA transcript as well as the
target protein. This approach to gene knockdown is particularly
attractive as it bypasses both translation and post-translational
mechanisms. In addition, by targeting mRNA, it also avoids the
risk of non-specific gene knockdown.
Our study also clearly demonstrates the importance of
appropriate reagent selection and validation. In testing three
different transfection reagents, we observed varying transfection
efficiencies but more importantly, we detected biological artefacts
present in HeLa cells that were treated with Lipofectamine 2000
or Matra but not in those that had been treated with GeneJuice.
Methods
Gold nanoparticle synthesis
Gold nanoparticles were prepared by the Turkevich method
[41]. Briefly, HAuCl4 was reduced using sodium citrate to yield
colloidal gold with a diameter of approximately 30 nm. To
prepare functionalised nanoparticles, 20 mL of oligonucleotide (59-
thiol-39-fluorescein isothiocyanate (FITC); prMJ514 441 pmol/mL
or prMJ515 415 pmol/mL) was added to 1 mL citrate-reduced Au
colloid (17 nM) and incubated for 3 h. Phosphate buffer (60 mM,
pH 7.4) was added to a final concentration of 10 mM and then
samples were salt-aged (NaCl, 2 M) to a final concentration of
0.05 M over a period of 24 h. Samples were left for 1 h after the
final salt addition and then centrifuged at 5000 rpm for 20 min,
the supernatant was removed and samples were re-suspended with
0.05 M phosphate buffer saline (PBS); the washing process was
repeated a further two times. Nanoparticles were resuspended to a
final concentration of 0.5 M in PBS and stored at 4uC.
Functionalized gold nanoparticles were stable at 4uC for up to 2
weeks, however a reduction in the intensity of the FITC
fluorescence signal was observed over this period of time due to
the deterioration of the FITC molecule.
In order to characterize nanoparticle size, functionalized gold
nanoparticles were diluted appropriately in dH2O to a total
volume of 1 mL and then analysed by dynamic light scattering
using a Zetasizer Nano ZS (Malvern Instruments). Three
measurements were made for each sample and each measurement
represents the output of 20 runs (Figure S1).
General Culture Conditions
HeLa cells (ATCC number CCL-2) were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
4 mM L-glutamine and 10% FBS at 37uC in an atmosphere that
contained 5% CO2.
Transfection and treatment of HeLa cells for hMT-IIa and
hMT-IIA knockdown studies
For each transfection, the required concentration of siRNA,
ssRNA or ssDNA (Eurofins MWG, Table S1) or ssDNA-
functionalized nanoparticles were transfected into 26105 HeLa
cells using GeneJuice (Novagen) as recommended by the
manufacturer’s instructions. Transfected cells were incubated for
16 hours and subsequently induced with 12.5 mM CdCl2 for
4 hours before mRNA and protein analysis.
RNA purification, cDNA synthesis and qPCR
Total RNA was prepared using the miRNeasy mini kit
(Qiagen). mRNA was isolated using Dynabeads mRNA Purifica-
tion Kit (Invitrogen) and was reverse transcribed using Superscript
II enzyme (Invitrogen). qPCR analysis was carried out in a
Lightcycler 480 (Roche) using Lightcycler Probes Master mix
(Roche). The nucleotide sequences of the primers used in each
reaction are shown in Table S1. Total hMT-IIa gene expression
was measured relative to the expression of B2M in control
sequence or hMT-IIa-specific sequence transfected cells. B2M is a
stably expressed chromosomal gene for beta-2-microglobulin [42].
Gold NP-Targeted Gene Expression Knockdown
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Protein analysis
Cell lysates were quantified using the Quant-iT protein assay kit
(Invitrogen), and 1 mg protein was separated on 4–12% Tris-
Acetate acrylamide gels. The protein bands were then transferred
to an Immobilon-P membrane by electroblotting. Metallothionein
(Dako; M0639) and a/b-tubulin (Cell Signalling; 2148) antibodies
were used for Western blotting which was performed using
standard conditions. Signal was detected with SuperSignal West
Pico Chemiluminescent substrate (Thermo Scientific) using the
GBOX/CHEMI-HR16-E-BOX Gel Documentation System
(Syngene) and analysed with the GeneSnap software (Syngene).
Membranes were stripped of antibodies and then re-probed for the
control protein (a-tubulin) to verify equal protein loading. Western
blot images were analyzed with ImageJ (http://rsb.info.nih.gov/
ij).
Microscopy
26105 HeLa cells were settled on glass coverslips for 2 h. These
cells were transfected with 0.2 or 1 nM FITC-NPs in the presence
and absence of Matra (IBA), Lipofectamine 2000 (Invitrogen) or
GeneJuice (Novagen). After 16 h, the cells were treated with
12.5 mM CdCl2 for 4 hours. Before visualizing the cells, coverslips
were gently washed three times in PBS at 37uC for live cell
microscopy (where a glass well was affixed to the coverslip so as to
maintain the cells in PBS during imaging). For fixed cell
microscopy, coverslips were washed three times in PBS for 5
minutes and this washing step was repeated after each of the
following steps: cells were fixed in 4% paraformaldehyde for 20
minutes; permeabilized with PBS containing 5% BSA, 0.1%
Triton X-100 for 5 minutes; blocked with PBS containing 5%
BSA, 0.05% Tween 20 for 1 h; incubated with 2 mg/mL anti-
LAMP1 (Santa Cruz; 18821) and/or anti-LC3A/B (Cell Signal-
ling; 4108) in PBS containing 5% BSA, 0.05% Tween 20 for 16 h
at 4uC; then incubated with 20 mg/mL anti-rabbit AF647 (Cell
Signalling; 4414) and/or anti-mouse AF546 (Cell Signalling; 4409)
in PBS containing 5% BSA, 0.05% Tween 20 for 2 h. Finally, cells
were incubated in 1 mg/mL DAPI for 5 minutes, washed in PBS
and then mounted using polyvinyl alcohol mounting medium with
DABCO (Sigma; 10981).
Cells were imaged using either a Zeiss Axio Observer inverted
microscope with an Andor LucaEM-R EMCCD camera and an
x63, 0.75 NA objective, or a Zeiss LSM510 laser scanning
confocal microscope with a x100, 1.45 NA objective. All images
were acquired using the same exposure and detector settings for
each spectral channel. Andor Solis software was used to acquire
images from the Observer microscope, which were then adjusted
so that, for each spectral channel, all images had an equal
background-corrected electron count range. Color conversion and
image overlays were performed using Corel Photo-Paint X3.
Confocal image overlays were processed using Zeiss LSM Image
Browser software.
For quantifying the fluorescence intensity from the FITC
channel in live cells, ImageJ (http://rsb.info.nih.gov/ij) was used.
A masking region was created by manually drawing around an
individual cell in a phase contrast image. This mask was then used
to measure the mean fluorescence intensity of the corresponding
cell in a FITC image. Cells that appeared to be dying or dividing
were not used for analysis. For all transfection conditions except
Matra, measurements were acquired from .32 cells taken from 8
or more images. As there were far fewer surviving Matra cells,
measurements for this transfection reagent were taken from 12
cells within 4 images.
Statistical analysis of image data
All quantification experiments contained n= 4 biological
replicates and experiments were repeated at least three times.
The data was transformed simply by taking logarithms. The log2
transformed data were analyzed in JAGS [43], a Gibbs sampler for
hierarchical models and CODA [44], a tool for examining Markov
Chain Monte Carlo runs. A two-level Bayesian ANOVA model
was used, modeling the intra-image variance at the first level and
inter-image variance at the second level. The likelihood was
specified as normally distributed, with an uninformative flat prior
on the variance. The first-level was specified as normally
distributed, with an uninformative inverse-gamma prior on the
variance. The second-level mean was given an uninformative
normal distribution.
The model calculated the posterior probability distribution over
the mean of the ratio of the treated to untreated total fluorescence.
The tails of this posterior distribution were compared to 1
(indicating no difference), to obtain a p-value. This p-value
indicated the posterior probability that there was no difference in
expression levels between the control and treatment samples.
Hence, a lower p-value would indicate a greater likelihood that
there was a difference between the control and treatment samples.
95% confidence intervals were also calculated for the mean ratio.
Results and Discussion
Characterization of the gold nanoparticles
As stated, the synthesis of gold nanoparticles was conducted
using standard methods, as described by the Turkevich method
[41]. The citrate salt acts as a reducing agent and forms a layer of
negatively charged citrate ions over the surface of the gold
nanoparticle, so inducing sufficient electrostatic repulsion to
generate uniform and generally spherical nanoparticles [45].
Endocytosis of gold nanoparticles is size dependent. In a study
in HeLa cells, Wang et al. [46] have previously demonstrated that
smaller nanoparticles (up to 40 nm) are internalized by endocy-
tosis whereas larger nanoparticles (70–110 nm) collect at the
cellular surface. In our hands, the mean diameter of the
synthesized gold nanoparticles prepared in this paper was
measured to be approximately 30+/210 nm (Figure S1) suggest-
ing that the most likely mechanism by which nanoparticles would
be expected to enter the cell was by endocytosis.
The surface of gold nanoparticles can be modified with a wide
variety of ligands including amine, carboxylate, isocyanide,
phosphine, and thiol groups [47–53]. In this study, gold
nanoparticles were modified with thiol-linkers and FITC-tagged
ssDNA sequences (59-SH-ssDNA-FITC-39) to make use of the
strong covalent bond that forms between gold and sulphur [54].
The final concentration of the ssDNA bound to the surface of the
gold nanoparticle was analysed by UV/Vis spectroscopy as
described by McKenzie et al. [55].
Nanoparticle stability can be quantified by measuring the zeta
potential of the colloidal system. If the particles in suspension have
a large negative or positive zeta potential then they repel each
other, reducing particle aggregation. However, if the particles have
low zeta potential values, then there is no force to prevent particle
flocculation. Generally, particles with zeta potentials more positive
than +30 mV or more negative than 230 mV are considered
stable [56]. The successful immobilization of DNA on the surface
of the gold nanoparticles was ascertained by measuring the
increase in the negative charge of the gold nanoparticles; the zeta
potential of the functionalized gold nanoparticles was approxi-
mately 230 mV [46,57].
Gold NP-Targeted Gene Expression Knockdown
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Transfection reagent-dependent HeLa cell death
In order to study the transfection efficiency of different
transfection reagents, we transfected FITC-tagged ssDNA-func-
tionalized nanoparticles into HeLa cells with a panel of three
transfection reagents with different formulations, as follows. Matra
(IBA) is a magnet-assisted nanoparticle-based transfection method
for intracellular delivery of nucleic acid, while Lipofectamine 2000
(Invitrogen) is a cationic liposome-based reagent and GeneJuice
(Novagen) consists of a non-toxic cellular protein and a small
amount of a proprietary polyamine.
At first, and most importantly, we observed that the phase-
contrast images of live HeLa cells showed that cells transfected
with nanoparticles were largely adherent, with shapes that
conformed to those of healthy HeLa cells for all the payloads
considered, i.e. unfunctionalised nanoparticles, coated with
sequences that were either not specifically targeted to a
mammalian transcript or with sequences that targeted the human
MT-IIa transcripts. While the transfection of nanoparticles with
GeneJuice or Lipofectamine did not appear to affect the
morphology of the HeLa cells, in contrast, very few HeLa cells
treated with Matra survived the transfection protocol (Figure 1).
Fluorescence imaging of live HeLa cells transfected with
functionalized gold nanoparticles (Figure 1) showed an increase
in cellular fluorescence with respect to untransfected control cells
(whose fluorescence signal results from native cellular autofluores-
cence). The measured whole-cell fluorescence emission of a
number of individual cells for each transfection method was
quantified and subsequent statistical analysis (Figure 2), using a
two-level Bayesian ANOVA model, confirmed that the level of
fluorescence from cells transfected with nanoparticles alone was
significantly higher than for control cells.
Interestingly, the Lipofectamine- and, to a lesser extent, the
GeneJuice-transfected live cells showed the presence of many
strongly fluorescent circular bodies that were rarely seen in cells
transfected with nanoparticles alone (Figure 1). To analyse these
further, transfected HeLa cells were fixed and studied by
fluorescent immunostaining for LC3A/B and LAMP1, protein
markers for autophagosomes and lysosomes respectively. Fluores-
cence imaging of the LC3A/B and LAMP1 proteins showed that
the signal intensity of these markers in untreated HeLa cells was
comparable to that in HeLa cells that contained functionalized
gold nanoparticles (Figure S2:647 and S2:546). When the
fluorescence corresponding to LC3A/B protein (red) was over-
layed with LAMP1 (green), there was no clear overlap between the
autophagosomes and lysosomes indicating that these were distinct
vesicular organelles (Figure S2:647+546, Figure 3).
As with the live cell studies, fixed cell fluorescence imaging of
HeLa cells showed the presence of functionalized gold nanopar-
ticles in both the cytoplasm and the nucleus, and increased signal
was observed in cells transfected with GeneJuice and Lipofecta-
mine (Figure S2:FITC). Bright circular bodies were again observed
in the FITC channel in the transfected HeLa cells, particularly in
the case of Lipofectamine-treated cells. Sometimes these bodies
were observed inside the cells (ca. 20%, n= 10) but frequently (ca.
80%, n= 10) they were seen on the perimeter of the cell, or even
outside the cell (Figure S2:FITC, Figure 3). Furthermore these
circular bodies exhibited fluorescence in the LC3A/B channel
(Figure S2:647, Figure 3) but not in the LAMP1 channel (Figure
S2:546, Figure 3). Confocal microscopy confirmed that these
LC3A/B containing vesicles co-localized with the FITC signal
carried by the functionalized gold nanoparticles (Figure 3).
Together the live cell and the immunofluorescence images suggest
that these are autophagosomes containing functionalized gold
nanoparticles that are either intracellular, are in the process of
being extruded or have already been extruded from the cell.
The largest number of these bodies was observed when
Lipofectamine was used as a transfection reagent; there were
fewer bodies when HeLa cells were transfected with GeneJuice
and such bodies were rare when no transfection reagent was used.
This suggested two possibilities, that the lipid-based transfection
reagent Lipofectamine enhanced exocytosis or that exocytosis was
a factor of the increased transfection efficiency in the presence of
Lipofectamine. Further experiments demonstrated that different
concentrations of transfected functionalized gold nanoparticles did
not affect the number of autophagosomes or extruded bodies and
so the generation of these bodies is likely to be related to the
Figure 1. Fluoresence microscopy images showing localization of FITC-tagged hMT-IIa-specific sequence functionalized
nanoparticles in live HeLa cells. HeLa cells were transfected with FITC-tagged hMT-IIa-specific sequence functionalized nanoparticles in the
absence (NanoParticles column) or the presence of the transfection reagents Matra, Lipofectamine 2000 or GeneJuice. Control cells were treated with
neither nanoparticles nor transfection reagents. The same signal intensity range was used for all FITC images. The scale bar represents 50 microns.
doi:10.1371/journal.pone.0099458.g001
Gold NP-Targeted Gene Expression Knockdown
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transfection reagent. This highlights the importance of thorough
validation of the reagents selected for use in nanoparticle-based
biological studies as well as the inclusion of appropriate biological
controls. For the knockdown studies, we selected GeneJuice as the
transfection reagent of choice as it increased the endocytosis of the
functionalized gold nanoparticles but did not introduce any
detectable artefacts.
Knockdown of MT gene expression
The majority of gene expression knockdown strategies use small
interfering RNA (siRNA)-based techniques [58–60]. In contrast,
most transfection studies of gold nanoparticles functionalized with
nucleotides reported to date have been based on DNA, possibly
due to its higher stability during the laboratory manipulations
involved in preparing the reagents. Here, we compared the
knockdown properties of ssDNA to the traditionally used siRNA
and ssRNA. The siRNA sequences we used were comprised of
sense and antisense RNA strands that have been annealed to form
the siRNA-based inhibitor, whereas the ssRNA and ssDNA
molecules consisted of single-stranded nucleic acid sequences that
were complementary to the coding sequence.
A system was designed for the detection and quantification of
hMT-IIa gene expression (Text S1, Figure S3 and Figure S4).
HeLa cells were transfected with control or hMT-IIa-specific
nucleotide sequences and the levels of hMT-IIa transcripts
following CdCl2 treatment were compared. When hMT-IIa-
specific siRNA, ssRNA or ssDNA sequences were transfected into
HeLa cells, a marked reduction in the levels of hMT-IIa mRNA
transcripts was observed (Figure 4) compared to random control
sequences, where no suppression was observed. At these concen-
trations (5 nM), the levels of the hMT-IIa transcripts in HeLa cells
transfected with siRNA, ssRNA and ssDNA were comparable
between the different oligonucleotide types (Figure 4), and similar
knockdown efficiency was observed with all three types of
inhibitory sequences (from 100% in the controls to 15613% for
siRNA, 28612% for ssRNA and 3264% for ssDNA). The siRNA
and ssRNA-based knockdown of hMT-IIa transcripts showed
greater variation between the biological replicates than when
ssDNA was used as the targeting nucleotide (Figure 4); coefficient
of variation (CV) for siRNA and ssRNA experiments were 0.5 and
0.3 respectively, whereas ssDNA showed a CV of 0.08. This may
reflect the greater stability of ssDNA compared to siRNA and
ssRNA.
We then defined the lowest effective concentration of hMT-IIa-
specific ssDNA required for the reduction of the hMT-IIa mRNA
and protein levels (Figure 5A and 5B). For concentrations of hMT-
IIa ssDNA between 0.2 to 2 nM, there was a noticeable decrease
in transcript levels (0.86 to 0.73 normalized fold reduction
compared to cells transfected with control sequences); while at
concentrations .5 nM, the levels of hMT-IIa transcripts in the
HeLa cells decreased to less than 5% of the initial hMT-IIa
transcript levels (Figure 5A). This reduction in the levels of the
hMT-IIa transcripts was also reflected at the protein level. As the
concentration of hMT-IIa ssDNA transfected into HeLa cells
Figure 2. A statistical analysis of the level of FITC fluorescence in HeLa cells transfected with nanoparticles, in the presence of
Lipofectamine, GeneJuice or Matra, compared to untransfected HeLa cells. HeLa cells were transfected with FITC-tagged hMT-IIa-specific
sequence functionalized nanoparticles in the absence or the presence of transfection reagents. The FITC fluorescence in the cells was quantified as
described in the methodology, and the levels of fluorescence in nanoparticle-transfected cells compared to those in untransfected cells. This multi-
level statistical analysis takes into account local variations within the cell population. The bars represent the region where there is a 95% probability
that the mean fluorescence increase lies within it. The dot represents the mean calculated effect size. Bars not crossing the 1 line show significant
evidence for an effect following transfection. The p-value indicates the probability that there was no difference in expression levels between the
control and treatment samples. Hence, a lower p-value indicates a greater likelihood that there was a difference between the transfected and the
untransfected cells.
doi:10.1371/journal.pone.0099458.g002
Gold NP-Targeted Gene Expression Knockdown
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increased, the levels of the hMT-IIA protein detected by Western
blot analysis decreased (Figure 5B, Table S2B). At a concentration
of 1000 nM ssDNA, the hMT-IIA protein was almost undetect-
able (Figure 5B).
The ssDNA-based reduction in the level of hMT-IIa mRNA
levels in the cells also occurred when the hMT-IIa-specific ssDNA
sequence functionalized nanoparticles were used, but not with
control sequences or bare gold nanoparticles. In this case, gold
nanoparticles functionalized with the same concentration of
ssDNA as that used above (5 nM) were transfected into HeLa
cells. There was no significant difference between the levels of
hMT-IIa mRNA transcripts between immobilized and free
oligonucleotide (Figure 6A vs. Figure 4), indicating that the
attachment of the ssDNA sequences to the gold nanoparticles did
not affect their ability to knock-down hMT-IIa mRNA levels. The
hMT-IIa ssDNA functionalized dependent decrease in hMT-IIa
mRNA transcripts was detected for 72 h (Figure S5). In addition,
the reduction in the level of the hMT-IIa transcript was greater
when GeneJuice was used as a transfection reagent, to assist
internalization of the ssDNA functionalized nanoparticles, than
when no tranfection reagent was present (Figure S6). A reduction
in hMT-IIA protein was also detected when nanoparticles
functionalized with hMT-IIa-specific ssDNA (ssDNA-NP) were
transfected into cells, but not when unmodified or control
sequence functionalized nanoparticles were used (Figure 6B, Table
S2C). These results demonstrate that the reduction in hMT-IIa
mRNA transcripts was also reflected at the level of hMT-IIA
protein.
Quantification of the Western blot images (Table S2B) showed
that the hMT-IIA protein was reduced to 50% of the initial levels
after transfection with 0.2 nM hMTIIa-specific ssDNA. At
concentrations of 1000 nM, hMTIIA protein was knocked down
to undetectable levels (Table S2B). To determine if ssDNA
functionalized gold nanoparticles behaved in a similar manner to
free ssDNA, DNA functionalized gold nanoparticles were trans-
fected into HeLa cells at concentrations between 0 nM and 1 nM;
which were non-toxic to the cells and were equivalent to the levels
of free ssDNA that reduced the level of the hMTIIA protein to
31% of the initial levels (Table S2B). When hMTIIa-specific
sequences were used to functionalize gold nanoparticles, the level
of hMTIIA protein expression in cells transfected with 1 nM
nanoparticles was reduced to 27% of that measured in HeLa cells
transfected with control-sequence functionalized nanoparticles or
unfunctionalized nanoparticles (Table S2C). This data shows that
the ssDNA-functionalized nanoparticles and free ssDNA elicited
similar concentration-dependent responses in CdCl2 treated HeLa
cells.
It is interesting to note that when the mRNA transcripts were
quantified, at concentrations of ssDNA .5 nM, the levels of
hMT-IIa were undetectable. In contrast, at the same ssDNA
concentration, hMT-IIA protein levels were still detected and full
knockdown was observed only at 1000 nM ssDNA. It is possible
that the antibody directed against the hMT-IIa protein detects
hMT isoforms other than hMT-IIa; and this non-specific activity
may be exacerbated by the relatively long half-life of the MT
proteins in the cell [61].
Each gold nanoparticle was functionalized with approximately
200 oligonucleotide strands [62] thus each particle has a finite
binding capacity for cellular hMTIIa gene transcript. In this
knockdown of gene expression study, we used a maximum of
1 nM gold nanoparticles in a transfection to avoid cytotoxicity. It
is possible that at these concentrations, not all the cellular hMTIIa
gene transcript would be bound to the transfected ssDNA
oligonucleotides and so some cellular transcripts may remain in
solution. To determine whether this was the case, total RNA
isolated from HeLa cells that had been transfected with
Figure 3. Confocal fluorescence microscopy images showing
localization of FITC-tagged hMT-IIa-specific sequence functio-
nalized nanoparticles in fixed HeLa cells. HeLa cells were
transfected with FITC-tagged hMT-IIa-specific sequence functionalized
nanoparticles in the presence of Lipofectamine. The overall FITC signal
was reduced so that the level of fluorescence from the observed circular
bodies was not saturating. The distribution of the LAMP1 protein
extends through the majority of the cytoplasmic area thus provides an
impression of the cell. In the overlayed image, the magenta regions
indicate the presence of cellular bodies in which the FITC signal from
the nanoparticles overlaps with the signal for the LC3A/B autophago-
somal protein marker. The scale bar represents 25 microns and the
images shown are all from a single z-plane (a 0.7 micron section).
doi:10.1371/journal.pone.0099458.g003
Figure 4. Reduction of hMTIIa gene expression in the presence
of siRNA, ssRNA and ssDNA. HeLa cells were untransfected (2),
transfected with 5 nM control (C) or 5 nM hMTIIa (MT)-specific siRNA,
ssRNA or ssDNA sequences using GeneJuice (Novagen). All samples
were induced with 12.5 mM CdCl2. The level of hMTIIa gene expression
(normalized to B2M) in untransfected and induced HeLa cells was
defined as 100% and all other fold inductions were expressed relative to
this. The error bars were calculated as 1 standard error of the mean
each way.
doi:10.1371/journal.pone.0099458.g004
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unfunctionalized, control or hMTIIA-specific sequence functio-
nalized gold nanoparticles and incubated for 16 h was analyzed
for levels of the hMTIIa transcript by qPCR. HeLa cells
transfected with unfunctionalized or control-sequence functiona-
lized nanopartices resulted in no reduction in the level of the
hMTIIa transcript whereas HeLa cells transfected with hMT-IIa
sequence functionalized nanoparticles resulted in a reduction in
the hMTIIa transcript to 11.1% (69.8%) of the initial levels
(Table 1). This indicates that there was little free hMT-IIa
transcript remaining in the cell after incubation with hMTIIa
sequence functionalized nanoparticles.
Discussion
For this study, we required a robust, rapidly growing, cell line
that could be reproducibly transfected [63] that was able to
express MT-IIA (and the expression of this gene needed to be
inducible [39,64]). Based on the requirements of this study, we
selected the HeLa cell line. The goal of this knockdown study
was the efficient quantifiable knockdown of target expression in
the context of the biological targeting event. The methods
available to measure target knockdown include Western blot
analysis of the target protein (which is semi-quantitative and
dependent on the availability of sensitive and specific antibodies)
and qPCR (which is quantitative and any gene of interest can be
analysed after the design of appropriate primers). The analysis of
the levels of target mRNA is robust and allows for reproducible
biological knockdown studies. It does not however measure the
effect of targeted knockdown. Based on our observations, we
propose that the measurement of both mRNA and protein are
required for a true reflection of specific target knockdown in the
cell.
The efficiency with which nanoparticles enter the cell has been
a major focus of research. While the nanoparticles themselves
enter the cell and the nucleus, it is clear that the use of transfection
reagents improves the efficiency of this process. We observed that
the use endocytosis-based transfection reagents (Lipofectamine
2000 and GeneJuice) resulted in an increased efficiency of
nanoparticle transfection. In contrast, the use of the nanoparti-
Figure 5. Levels of hMT-IIa in HeLa cells transfected with
increasing concentrations of hMT-IIa or control ssDNA. Trans-
fections were carried out with GeneJuice (Novagen). (A) Levels of hMT-
IIa mRNA. All samples were induced samples with 12.5 mM CdCl2. Total
hMT-IIa activity relative to B2M in cells transfected with varying levels of
ssDNA was normalized to hMT-IIa-B2M expression in cells transfected
with 0 nM ssDNA giving us a value for hMT-IIa activity in the presence
of x nM ssDNA. The levels of hMT-IIa transcript in cells transfected with
control ssDNA (C) was set to 1.0. The level of hMT-IIa gene expression
(MT) in cells transfected with hMT-IIa ssDNA was compared to the levels
of hMT-IIa in cells transfected with control ssDNA at each concentration
providing a measure of the reduction in hMT-IIa activity in hMT-IIa
ssDNA transfected compared to those transfected with control ssDNA.
The error bars were calculated as 1 standard error of the mean each
way. (B) Levels of hMT-IIa protein. All samples were induced with
12.5 mM CdCl2. HeLa cells were transfected with hMT-IIa-specific ssDNA
(ssDNA). Proteins extracted from HeLa cells were analyzed using
Western blots and hMT-IIa-specific antibodies. a/b tubulin was used as a
loading control. Quantification of the levels of hMT-IIA protein relative
to a/b tubulin is shown in Table S2B.
doi:10.1371/journal.pone.0099458.g005
Figure 6. Levels of hMTIIa in HeLa cells transfected with gold
nanoparticles. Transfections were carried out with GeneJuice (Nova-
gen). (A) Levels of hMT-IIa mRNA. HeLa cells were transfected with 5 nM
unfunctionalized (2), 5 nM control (C) or 5 nM hMTIIa (MT)-specific
ssDNA functionalized gold nanoparticles. Samples were treated with
12.5 mM CdCl2. The level of hMTIIa gene expression (normalized to B2M)
in untransfected and induced HeLa cells was defined as 100% and all
other fold inductions were expressed relative to this. The error bars
were calculated as 1 standard error of the mean each way. (B) Levels of
hMT-IIa protein. Induced samples were treated with 12.5 mM CdCl2 (+
Cd). HeLa cells were transfected with unfunctionalized (2), control (C)
or hMT-IIa (MT) ssDNA-functionalized nanoparticles. Proteins extracted
from HeLa cells were analyzed using Western blots and hMT-IIa-specific
antibodies. a/b tubulin was used as a loading control. Quantification of
the levels of hMT-IIA protein relative to a/b tubulin is shown in Table
S2C.
doi:10.1371/journal.pone.0099458.g006
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cle-based transfection reagent Matra under these conditions
resulted in cell death. As the efficiency of target delivery directly
influences knockdown efficiency, it is important both to better
understand how these transfection reagents enhance particle
delivery and to develop reagents for the targeted delivery of
nanoparticles into the cells. The increased efficiency of targeted
ssDNA delivery directly to the nucleus means that lower
concentrations of inhibitory sequences need to be used to elicit a
biological effect. This is an advantage when dealing with
potentially toxic sequences or genes that are expressed at higher
levels.
In this report, we defined the ssDNA-functionalized gold
nanoparticles by the concentration of DNA attached to the
nanoparticles. Based on the data that we collected, we observed
that that the ssDNA behaved comparably at similar concentrations
whether it was free or functionalized onto gold nanoparticles. The
advantages of using nanoparticles are numerous; including the fact
that the functionalized nanoparticles entered HeLa cells both in
the presence and the absence of transfection reagents which could
negate the need for transfection reagents. This is an important
factor when considering in vivo experiments. In contrast, the use of
transfection reagents enhanced transfection efficiency, allowing the
use of lower concentrations of functionalized nanoparticles in
biological experiments, with direct effects on the cost of the
reagents. The nanoparticles provided a structure onto which to
bind the ssDNA sequences. This allows the same ssDNA-
functionalized nanoparticles to be used in both knockdown and
fluorescence microscopy studies, providing directly comparable
biological and visual data. Finally, it has been shown previously
that antibody-functionalized nanoparticles can be used to target
particular cell types; hence attaching both targeting antibodies and
inhibitory ssDNA to these nanoparticles is an attractive option and
the next step.
Conclusions
In this article, we demonstrate (a) that the validation of
experimental reagents and the inclusion of appropriate controls
is essential to avoid the collection and over-interpretation of
artifacts in the data and (b) that ssDNA inhibitory sequences are as
effective as ssRNA and siRNA inhibitory sequences at targeting
knockdown of a specific gene target, both at the mRNA transcript
and the protein level.
Supporting Information
Figure S1 Measuring the size of a colloidal suspension
of the FITC-labelled ssDNA-functionalized gold nano-
particles by dynamic light scattering. Three particle
number-based size distribution measurements were performed
on a suspension of nanoparticles in dH2O. Averaging the three
measurements (each of which is the output of 20 runs) gave a peak
diameter of 31 nm.
(TIF)
Figure S2 Fluorescence microscopy images showing
localization of FITC-tagged hMT-IIa-specific sequence
functionalized nanoparticles in fixed HeLa cells. (A) HeLa
cells were transfected with FITC-tagged hMT-IIa-specific se-
quence functionalized nanoparticles in the absence or the presence
of transfection reagents Lipofectamine or GeneJuice. The control
samples include HeLa cells probed for the lysosomal marker with
anti-LAMP1 and anti-Alexa546 and for the autophagosomal
marker with anti-LC3A/B and anti-Alexa647. Finally, control
samples represent HeLa cells that were probed with only a
secondary antibody. Comparable results were obtained for anti-
Alexa546 alone and anti-Alexa647 alone, and the data for anti-
Alexa647 is shown here. A fixed signal intensity range for each
spectral channel was used for fluorescence images. Circles have
been drawn around structures with signal in the anti-FITC and the
anti-Alexa647 channels. The scale bar represents 50 microns. (B)
Images for HeLa cells transfected with FITC-tagged hMT-IIa-
specific sequence functionalized nanoparticles in the presence of
Lipofectamine (from Figure S2A) have been enlarged. Circles
show structures with signal in the anti-FITC and the anti-
Alexa647 channels; the scale bar represents 50 microns.
(TIFF)
Figure S3 Induction of hMTIIa gene expression in
increasing CdCl2 concentrations in HeLa cells. Expression
of hMTIIa was normalized to that of B2M, a stably-expressed
chromosomal gene for beta-2-microglobulin. The level of hMTIIa
gene expression in uninduced HeLa cells was defined as the basal
level of expression (1 arbitrary unit) and all other fold inductions
were expressed relative to this. The error bars were calculated as 1
standard error of the mean each way.
(TIF)
Figure S4 Induction of hMTIIa expression in the
presence of Cd. Untransfected HeLa cells were treated with
12.5 mM CdCl2 (+Cd). (A) The level of hMTIIa gene expression
(normalized to B2M) in induced HeLa cells was defined as 100%
and the fold induction of the uninduced cells was expressed
relative to this. The error bars were calculated as 1 standard error
of the mean each way. (B) The level of hMT-IIa protein in induced
HeLa cells. Proteins extracted from HeLa cells were analyzed
using Western blots and hMT-IIa-specific antibodies. a/b tubulin
was used as a loading control. Quantification of the levels of hMT-
IIA protein relative to a/b tubulin is shown in Table S2A.
(TIF)
Figure S5 Reduction of hMTIIa gene expression in the
presence of Cd over 72 hours. HeLa cells were transfected
with 5 nM control (C) or 5 nM hMT-IIa (MT) specific ssDNA
sequence functionalized nanoparticles. Transfections were carried
out with GeneJuice (Novagen). Total hMT-IIa activity relative to
B2M in cells transfected with 5 nM hMT-IIa (MT) specific ssDNA
sequence functionalized nanoparticles was normalized to hMT-
IIa-B2M expression in cells transfected with control sequence
functionalized nanoparticles. The levels of hMT-IIa transcript in
cells at Time= 0 h was set to 100%. The level of hMT-IIa gene
Table 1. Quantification of the levels of hMT-IIa transcript in
HeLa cells after treatment with ssDNA-functionalized
nanoparticles.
Gold nanoparticles % hMT-IIA
- 10066.0
C 114.5610.4
MT 11.169.8
Induced samples were treated with 12.5 mM CdCl2 (+Cd). HeLa cells were
transfected with 5 nM unfunctionalized (2), 5 nM control (C) or 5 nM hMTIIa
(MT)-specific ssDNA functionalized gold nanoparticles. The level of hMTIIa gene
expression (normalized to B2M) in HeLa cells transfected with unfunctionalized
(2)gold nanoparticles was normalized to 100% and all other fold inductions
were expressed relative to this. The error bars were calculated as 1 standard
error of the mean each way and represented as a percentage of the activity.
doi:10.1371/journal.pone.0099458.t001
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expression (MT) in cells transfected with hMT-IIa ssDNA
functionalized gold nanoparticles was compared to the levels of
hMT-IIa in cells transfected with control ssDNA functionalized
gold nanoparticles at each time point providing a measure of the
reduction in hMT-IIa activity in cells transfected with hMT-IIa
(MT) compared to those transfected with control (C) ssDNA
functionalized nanoparticles. The error bars were calculated as 1
standard error of the mean each way.
(TIFF)
Figure S6 The effect of the transfection reagent Gene-
Juice on the knockdown of hMTIIa gene expression in
the presence of Cd. HeLa cells were transfected with 5 nM
control (C) or 5 nM hMT-IIa (MT) specific ssDNA sequence
functionalized nanoparticles. Total hMT-IIa activity relative to
B2M in cells transfected with 5 nM hMT-IIa (MT) specific ssDNA
sequence functionalized nanoparticles was normalized to hMT-
IIa-B2M expression in cells transfected with control sequence
functionalized nanoparticles. The levels of hMT-IIa transcript in
cells transfected with control (C) sequence functionalized nano-
particles was set to 100%. The level of hMT-IIa gene expression
(MT) in cells transfected with hMT-IIa ssDNA functionalized gold
nanoparticles was compared to the levels of hMT-IIa in cells
transfected with control ssDNA functionalized gold nanoparticles
providing a measure of the reduction in hMT-IIa activity in cells
transfected with hMT-IIa (MT) compared to those transfected
with control (C) ssDNA functionalized nanoparticles. The error
bars were calculated as 1 standard error of the mean each way.
(TIFF)
Table S1 Primers used in this study.
(DOCX)
Table S2 Quantification of the reduction in hMT-IIA
protein in HeLa cells treated with ssDNA or ssDNA-
functionalized nanoparticles in the Western blots.
Induced samples were treated with 12.5 mM CdCl2 (+Cd).
(DOC)
Text S1 Design and optimization of a system for MT
gene expression analysis.
(DOCX)
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